News headlines about OPKO Health (NASDAQ:OPK) have been trending somewhat positive on Saturday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OPKO Health earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.6569781959385 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media stories that may have impacted Accern’s rankings:
Several research analysts have weighed in on OPK shares. Zacks Investment Research lowered OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 24th. JPMorgan Chase lowered OPKO Health from a “neutral” rating to an “underweight” rating and set a $7.00 price objective on the stock. in a report on Friday, March 2nd. BidaskClub lowered OPKO Health from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. ValuEngine lowered OPKO Health from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Finally, Cantor Fitzgerald set a $20.00 price objective on OPKO Health and gave the company a “buy” rating in a report on Thursday, March 1st. Four research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $11.29.
Shares of NASDAQ OPK traded down $0.14 during mid-day trading on Friday, reaching $3.07. 3,195,852 shares of the company traded hands, compared to its average volume of 4,464,873. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.98 and a current ratio of 1.14. The firm has a market cap of $1,795.91, a price-to-earnings ratio of -10.59 and a beta of 1.56. OPKO Health has a fifty-two week low of $2.66 and a fifty-two week high of $7.90.
OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.04). The company had revenue of $193.70 million for the quarter, compared to analyst estimates of $307.44 million. OPKO Health had a negative net margin of 28.93% and a negative return on equity of 7.87%. equities research analysts forecast that OPKO Health will post -0.48 earnings per share for the current year.
In other OPKO Health news, CEO Phillip Md Et Al Frost bought 10,000 shares of the stock in a transaction on Thursday, April 5th. The shares were purchased at an average price of $3.25 per share, with a total value of $32,500.00. Following the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $9,974,090.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders acquired a total of 1,758,365 shares of company stock worth $6,375,328 in the last ninety days. Insiders own 40.19% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “OPKO Health (NASDAQ:OPK) Given Media Impact Rating of 0.02” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/opko-health-opk-receiving-somewhat-positive-press-coverage-study-finds.html.
About OPKO Health
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.